Q-omics provides the consensus-scored TBX19 profile across patient tissues and cancer cell-line models. TBX19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TBX19 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TBX19 RNA expression shows 18,708 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where TBX19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX19 survival associations across molecular data types. TBX19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX19 RNA expression–survival associations across cancer types. High TBX19 expression shows unfavorable associations in LIHC, ACC, COAD, LGG and UCEC, but favorable associations in SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TBX19 RNA expression.
This table summarizes TBX19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TBX19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX19 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, BLCA, LIHC and KIRP. The KIRC box plot shows higher TBX19 RNA expression in tumor versus normal tissue (log2 FC = +1.105, t-test p < 0.001).
This table shows molecular features associated with TBX19 in patient tissues and cancer cell lines. In patient samples, TBX19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
